The effectiveness of Danazol therapy in postmenopausal women affected by endometrial hyperplasia

A. Sedati, L. Mariani, R. Giovinazzi, M. Yacoub, G. Atlante

Research output: Contribution to journalArticle

Abstract

Forty eight atients in postmenopause affected by histologically confirmed endometrial hyperplasia (34 with simplex and 14 with complex forms) were administered Danazol therapy, 400 mg/day for 3 consecutive months. At the end of treatment, regression of the endometrial hyperplasia was histologically ascertained in 46 patients (95.9%) with disappearance of the metrorrhagia Endometrial atrophy was obtained in 75% of the cases, while secretive (14.7%) or proliferative (6.2%) aspects resulted in the others. Only 2 patients (4.1%) showed persistence of the hyperplastic endometrium. On the basis of this experience, treatment with Danazol appears to be effective and safe with only scarce and transient side effects. This therapy is therefore proposed as a valid alternative to progestogen therapy in cases of postmenopausal endometrial hyperplasia.

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalClinical and Experimental Obstetrics and Gynecology
Volume19
Issue number3
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'The effectiveness of Danazol therapy in postmenopausal women affected by endometrial hyperplasia'. Together they form a unique fingerprint.

  • Cite this